Investigators at Massachusetts General Hospital (MGH) and Harvard Medical School will use data from Illumina’s Sentrix®HumanHap300 BeadChips and Infinium® assay reagents to perform a 2,200-sample, whole-genome association study of Amyotrophic Lateral Sclerosis (ALS).

Adrian Ivinson, Ph.D. asserts that this will be the largest genetic study to date of ALS. The study is projected to provide significant insight into the etiology of the disease and is expected to lead to improved diagnosis, earlier intervention, and ultimately, more effective treatment.

Previous articleDNAPrint Genomics and Emory University Partner on Genetic Ancestry Test
Next articleMonsanto to Acquire Delta and Pine Land Company